Anti-TNF (Clinical) is under clinical development by 180 Life Sciences and currently in Phase II for Dupuytren Contracture. According to GlobalData, Phase II drugs for Dupuytren Contracture does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Anti-TNF (Clinical) LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Anti-TNF (Clinical) overview

Anti-TNF monoclonal antibody is under development for the treatment of Dupuytren's contracture, post operative cognitive dementia (POCD) and non-alcoholic steatohepatitis (NASH). The drug candidate is administered through subcutaneous and intraarticular route.. It targets the tumor necrosis factor alpha. It is a repurposed drug of adalimumab.

The drug candidate was also under development for the treatment of periarticular disease and frozen shoulder syndrome. 

180 Life Sciences overview

180 Life Sciences is developing new treatments for one of the world’s biggest drivers of disease. The company is headquartered in the US.

For a complete picture of Anti-TNF (Clinical)’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.